ReviewFrontiers in immunology2020
Innate Lymphocytes in Psoriasis.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.JCI insight · 2025Trial
- Role of transient receptor potential channels on pathogenesis and treatment of psoriasis.Inflammopharmacology · 2026Review
- T helper 17 cells and group 3 innate lymphoid cells define a spectrum of psoriasis endotypes.Frontiers in immunology · 2026Review
- A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.American journal of clinical and experimental immunology · 2026Review
- Phantom of the immunologic opera: Unmasking the role of innate lymphoid cells (ILC) in inborn errors of immunity (IEI).Journal of human immunity · 2025Review
- Rutin ameliorates imiquimod-induced psoriasis-like skin lesions by inhibiting oxidative stress injury and the inflammatory response in mice via the Keap1/Nrf2 signaling pathway.Scientific reports · 2025Article
- Psoriasis: an emerging risk factor for ischemic stroke?Frontiers in neurology · 2025Review
- Causal effect of psoriasis on aortic valve stenosis: a two-sample Mendelian randomization study.Journal of geriatric cardiology : JGC · 2024Article
- Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis.Biomolecules · 2024Review
- The Immunology of Psoriasis-Current Concepts in Pathogenesis.Clinical reviews in allergy & immunology · 2024Review
- Single-cell sequencing analysis and multiple machine-learning models revealed the cellular crosstalk of dendritic cells and identified FABP5 and KLRB1 as novel biomarkers for psoriasis.Frontiers in immunology · 2024Article
- A Transcriptome-Wide Analysis of Psoriasis: Identifying the Potential Causal Genes and Drug Candidates.International journal of molecular sciences · 2023Article
- HIV-Associated Immune Dysregulation in the Skin: A Crucible for Exaggerated Inflammation and Hypersensitivity.The Journal of investigative dermatology · 2023Review
- Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets.Frontiers in immunology · 2023Review
- Evidence-based modalities in the management of Psoriasis and Psoriatic arthritis.Bioinformation · 2023Article
- Alleviating psoriatic skin inflammation through augmentation of Treg cells via CTLA-4 signaling peptide.Frontiers in immunology · 2023Article
- The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry.Cellular & molecular immunology · 2022Article
- The role of unconventional T cells in maintaining tissue homeostasis.Seminars in immunology · 2022Review
- Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies.Journal of nanobiotechnology · 2022Review
- Impact of ROS-Dependent Lipid Metabolism on Psoriasis Pathophysiology.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Skin is a fundamental component of our host defense system that provides a dynamic physical and chemical barrier against pathogen invasion and environmental insults. Cutaneous barrier function is mediated by complex interactions between structural cells such as keratinocytes and diverse lineages of immune cells. In contrast to the protective role of these intercellular interactions, uncontrolled immune activation can lead to keratinocyte dysfunction and psoriasis, a chronic inflammatory disease affecting 2% of the global population. Despite some differences between human and murine skin, animal models of psoriasiform inflammation have greatly informed clinical approaches to disease. These studies have helped to identify the interleukin (IL)-23-IL-17 axis as a central cytokine network that drives disease. In addition, they have led to the recent description of long-lived, skin-resident innate lymphocyte and lymphoid cells that accumulate in psoriatic lesions. Although not completely defined, these populations have both overlapping and unique functions compared to antigen-restricted αβ T lymphocytes, the latter of which are well-known to contribute to disease pathogenesis. In this review, we describe the diversity of innate lymphocytes and lymphoid cells found in mammalian skin with a special focus on αβ T cells, Natural Killer T cells and Innate Lymphoid cells. In addition, we discuss the effector functions of these unique leukocyte subsets and how each may contribute to different stages of psoriasis. A more complete understanding of these cell types that bridge the innate and adaptive immune system will hopefully lead to more targeted therapies that mitigate or prevent disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.